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Interestingly, we successfully isolated infectious virus from
five of five samples from patients with Tx (obtained 4–28 d after
admission to the ICU), but, in line with data from Wölfel and
colleagues (9), we were unable to detect infectious virus after Day 7
in immunocompetent control patients (zero of four patients).
Limitations. First, the sample size of our study is
limited, but the significant findings with potential major
impact on patient management are of great importance.
Second, three patients remained under intensive care treatment on the
day of data censoring, resulting in an unknown outcome. Third, some
cases had incomplete documentation of clinical data, missing
laboratory-testing results, or both.
Conclusions. To our knowledge, this is the first
comprehensive report on COVID-19 in patients with a
history of HSCT that focuses on virological parameters. In
these patients, as compared with immunocompetent patients,
prolonged shedding of infectious virus, viremia, and high viral loads
in respiratory samples highlight the need of the immune system for
viral control but also indicate virus-induced mortality and a higher
risk for transmission to other patients and medical staff. n
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Risk Factors for Mortality after COVID-19 in Patients
with Preexisting Interstitial Lung Disease
To the Editor:
Patients with preexisting interstitial lung disease (ILD) may be at high risk
for severe coronavirus disease (COVID-19) because of impaired lung
function, propensity to develop acute exacerbation of pulmonary fibrosis,
or immunomodulatory medications that may interact with viral clearance
or pathogenesis (1, 2). Previous studies found that patients with ILDs had
an increased risk of death compared with control subjects matched for
age, sex, comorbidities, and/or race (3, 4). However, whether the type of
ILD may influence the outcome of COVID-19 is unknown. Here, we
aimed to compare mortality of COVID-19 between patients with fibrotic
idiopathic ILD, including idiopathic pulmonary fibrosis (IPF), with those
with other types of ILD.
In this multicentric observational survey of specialized
centers, we analyzed the survival of COVID-19 in patients with
ILDs and compared mortality rates among those with fibrotic
idiopathic ILDs, including IPF, with those with other ILDs.
Patients were eligible if they had preexisting ILD and if they had
COVID-19 during the study period confirmed by RT-PCR or
definite clinical manifestations (acute onset of fever, flu-like
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symptoms, headache, and anosmia), typical features on chest
computed tomography and positive serology for severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients
with lung transplantation were excluded. Consecutive cases
were collected using a deidentified case report form through
the French rare lung disease network (OrphaLung) between the
onset of the outbreak in France to May 28, 2020. Data collected
included demographics, medical history, comorbidities, last
available lung function in stable condition, and treatment received
at the time of COVID-19. The primary outcome was death,
censored at Day 30 of COVID-19. No imputation was applied for
missing data. Univariable and multivariable Cox regression
analyses were used to investigate predictors of mortality. For
multivariable analysis, we included into the model variables that
were associated with mortality in univariable analysis with a
P value of less than 0.10, as well as glucocorticoid therapy used
to treat COVID-19, as it was considered clinically relevant.
Medications to treat ILD were excluded from the prediction model
to limit collinearity with the underlying diagnosis. This study was
formally approved by the institutional review boards of the French
learned society for respiratory medicine (Comité d’Ethique Pour la
Recherche Observationnelle 2020-036; August 25, 2020) and the
Hospices Civils de Lyon (May 13, 2020), which waived the need for
written informed consent (April 14, 2020).
Table 1. Main Characteristics of the Study Population and Outcomes by ILD Diagnosis
Fibrotic Idiopathic ILD (n=48) Other ILDs (n=75) All (N=123) P Value
Patient characteristics
Sex, n (%) 0.04
F 11 (23) 31 (41) 42 (34)
M 37 (77) 44 (59) 81 (66)
Age, mean6SD, yr 71611 60618 64616 0.02
Body mass index, mean6SD, kg $m22 2664 276 3 276 5 0.29
Comorbidities, n (%)
Obesity 8 (17) 16 (21) 24 (20) 0.55
Hypertension 24 (50) 29 (39) 53 (43) 0.26
Cardiovascular disease 16 (33) 12 (16) 28 (23) 0.03
Diabetes mellitus 17 (35) 19 (25) 36 (29) 0.27
Chronic kidney disease 4 (8) 7 (9) 11 (9) 0.81
Cancer or hemopathy 3 (6) 4 (5) 7 (6) 0.86
Pulmonary hypertension 7 (15) 8 (11) 15 (12) 0.50
Pulmonary characteristics
mMRC, mean6SD 1.96 1.0 1.761.1 1.761.1 0.26
FVC% predicted, mean6SD 766 22 81625 79624 0.28
FVC% categories, n (%) 0.14
,50 7 (15) 4 (5) 11 (15)*
50–70 8 (17) 19 (25) 27 (36)*
.70 27 (56) 45 (60) 72 (96)*
Corrected DLCO% predicted, mean6SD 46617 54621 51620 0.06
DLCO% categories, n (%) 0.62
,40 12 (25) 15 (20) 27 (22)
40–60 13 (27) 22 (29) 35 (28)
.60 12 (25) 25 (33) 37 (30)
Oxygen supplementation at home, n (%) 12 (25) 10 (13) 22 (18) 0.12
Treatment at baseline, n (%)
Antifibrotic medication 12 (25) 0 (0) 12 (10) <0.01
Glucocorticoids 11 (23) 36 (48) 47 (38) 0.01
Immunosuppressive drugs 10 (21) 35 (47) 45 (37) <0.01
COVID-19–related medications, n (%)
Any medication 18 (37) 25 (33) 43 (35) 0.64
Lopinavir/ritonavir 2 (4) 6 (8) 8 (7) 0.40
Azithromycine 8 (17) 6 (8) 14 (11) 0.14
Hydroxychloroquine 7 (15) 8 (11) 15 (12) 0.52
Glucocorticoids 5 (10) 9 (12) 14 (11) 0.79
Outcomes, n (%)
Hospital admission 0.37
Not hospitalized 5 (10) 15 (20) 20 (16)
Hospitalized, not in ICU 32 (67) 45 (60) 77 (63)
Hospitalized in ICU 11 (23) 15 (20) 26 (21)
Dead at Day 30 17 (35) 14 (19) 31 (25) 0.04
Definition of abbreviations: COVID-19= coronavirus disease; ILD= interstitial lung disease; mMRC=modified Medical Research Council.
Comparisons used x2 or Student’s t test when appropriate. Bold indicates P, 0.05.
*These percentages were calculated from available data.
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A total of 123 patients were included (Table 1), with a median age
of 64 years (interquartile range, 58–74 yr), and 66% were of male sex.
Forty-eight patients (39%) had fibrotic idiopathic ILD, including IPF
(n=20; median age, 72 yr), idiopathic nonspecific pneumonia (n=8;
median age, 66.5 yr), and other fibrotic idiopathic ILDs (n=20;
median age, 73.5 yr). Other diagnostic categories included connective
tissue disease–associated ILD (n=27; median age, 57 yr), systemic
vasculitis (n=7; median age, 61 yr), sarcoidosis (n=16; median age,
56 yr), and other ILDs (n=25; median age, 64.5 yr). Patients were
receiving antifibrotic drugs (10%), glucocorticoids (38%), or other
immunosuppressive drugs (37%). COVID-19 was confirmed by RT-
PCR in 91% of patients and by symptoms, computed tomography
scan, and serology in 9% of patients. COVID-19–related medications
were prescribed for COVID-19 in 35% of cases.
Hospital admission was required in 84% of patients (90% of those
with fibrotic idiopathic ILD and 80% of those with other ILDs),
including 21% in ICUs. According to the reporting physician,
admission modalities were appropriate in all cases (i.e., no patient was
denied admission because of bed unavailability). At Day 30 of COVID-
19, 17 of 48 (35%) patients with fibrotic idiopathic ILD had died
compared with 14 of 75 (19%) of those with other ILDs (P=0.04). The
median time between diagnosis and death was 8 days (interquartile
range, 4–15 d). Death was related to COVID-19 in all cases, including
four in whom COVID-19 triggered an acute exacerbation of IPF.
On univariable Cox regression analysis, mortality was
significantly associated with male sex, increasing age, an underlying
diagnosis of fibrotic idiopathic ILD compared with other ILDs,
comorbidities (hypertension, cardiovascular disease, cancer or
hemopathy, and pulmonary hypertension), lower FVC, lower
DLCO, chronic use of oxygen supplementation at home (at rest
or exercise), and treatment with antifibrotic drugs (Table 2). On
Cox multivariable analysis, increasing age, male sex, history of
cancer/hemopathy, and the chronic use of oxygen supplementation
at home remained independently predictive of mortality (Table 2).
Here, we report a series of 123 patients with ILD who had
COVID-19 and were followed in the French network of rare
pulmonary disease expert centers. This relatively low number likely
reflects that patients with ILD stayed at home during the lockdown
period and rigorously adopted preventive measures to protect
themselves from infection (5).
The case fatality rate was 35% among subjects with idiopathic
fibrotic ILD and was 19% in those with another ILD. Of note, the
mortality among subjects with an ILD other than fibrotic idiopathic
ILD was comparable with that reported in the global French
population hospitalized for COVID-19 (18.1%) (6). Multivariable
analysis indicated that the greater mortality among subjects
with fibrotic idiopathic ILD was attributable to age and
Table 2. Association with Mortality of Clinical Characteristics, Comorbidities, Lung Function, and Treatment by Cox Regression
Analysis
Univariable Analysis Multivariable Analysis
HR (95% CI) P Value HR (95% CI) P Value
Sex, M/F 4.22 (1.47–12.06) 0.01 3.90 (1.17–13.04) 0.03
Age, yr 1.07 (1.03–1.10) <0.01 1.07 (1.04–1.11) <0.01
Body mass index, kg $m22 1.02 (0.96–1.09) 0.51 — —
Underlying ILD, fibrotic/other 2.15 (1.06–4.35) 0.04 — —
Comorbidities, yes/no
Obesity 1.01 (0.41–2.47) 0.99 — —
Hypertension 2.48 (1.18–5.21) 0.02 — —
Cardiovascular disease 3.20 (1.55–6.59) <0.01 — —
Diabetes mellitus 1.46 (0.69–3.06) 0.32 — —
Chronic kidney disease 1.81 (0.63–5.20) 0.27 — —
Cancer or hemopathy 3.21 (1.12–9.21) 0.03 5.82 (1.88–18.08) <0.01
Pulmonary hypertension 2.88 (1.22–6.83) 0.02 — —
Pulmonary characteristics
FVC% predicted 0.98 (0.96–0.99) 0.02 — —
Corrected DLCO% predicted 0.96 (0.94–0.99) <0.01 — —
Oxygen supplementation at home 4.25 (2.02–8.91) <0.01 4.56 (2.13–9.78) <0.01
Treatment at baseline, yes/no
Antifibrotic medication 3.09 (1.27–7.55) 0.01 — —
Glucocorticoids 1.06 (0.51–2.18) 0.88 — —
Immunosuppressive drugs 0.58 (0.26–1.30) 0.19 — —
COVID-19–related medications, yes/no
Any 1.43 (0.70–2.92) 0.32 — —
Lopinavir/ritonavir 1.61 (0.49–5.30) 0.43 — —
Azithromycine 0.23 (0.03–1.72) 0.15 — —
Hydroxychloroquine 1.58 (0.60–4.11) 0.35 — —
Glucocorticoids 1.15 (0.40–3.28) 0.80 — —
Definition of abbreviations: CI = confidence interval; COVID-19 = coronavirus disease; HR = hazard ratio; ILD = interstitial lung disease.
Bold indicates P, 0.05.
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comorbidities already identified as risk factors of severity in
COVID-19 (7, 8).
Chronic home oxygen supplementation was also associated with
greater mortality, reflecting the severity of the underlying ILD,
independently of the ILD diagnostic subgroup. This finding is
consistent with that of a large prospective observational cohort study,
in which peripheral oxygen saturation on room air lower than 92%
was significantly associated with in-hospital mortality (7), and with a
study of patients with ILD before developing COVID-19, in which
an FVC of ,80% predicted was associated with mortality (4).
Mortality in our cohort was directly related to COVID-19 and
followed an acute exacerbation of fibrotic ILD triggered by the viral
infection in four cases. However, distinguishing an infection from a
triggered acute exacerbation can be challenging (9). Long-term
treatment with glucocorticoids or immunosuppressive drugs was
not associated with a worse prognosis, in contrast to previous
suggestions (10).
This study has limitations, including the small sample
size, retrospective design, and absence of model validation.
Individuals who were not hospitalized may have been missed; however,
this does not influence the case fatality rate among patients who were
admitted. A longer follow-up is required to assess potential irreversible
pulmonary fibrosis secondary to COVID-19 (11) because delayed
improvement may occur (12).
In conclusion, this study found a high mortality rate
due to COVID-19 in patients with preexisting fibrotic
idiopathic ILD compared with those with other ILDs, which
was mostly attributable to age, male sex, history of cancer,
and severity of the underlying ILD as reflected by the chronic
use of supplemental oxygen. The potential long-term impact
of COVID-19 on the course of ILD remains to be determined. n
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Julie Perrin (Metz), Stéphane Raymond (Metz), Yasmine Rebaı̈ne (Lyon),
Martine Reynaud-Gaubert (Marseille), Frédéric Schlemmer (Créteil),
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In Search of “Hepatic Factor”: Lack of Evidence for
ALK1 Ligands BMP9 and BMP10
To the Editor:
Considerable evidence suggests that the liver produces or modifies a
circulating factor critical for preventing pulmonary arteriovenous
malformations (PAVMs). In hepatopulmonary syndrome, liver
dysfunction is associated with hypoxemia secondary to PAVMs, and
PAVMs are reversed by liver transplantation (1). Additionally,
portosystemic shunts that allow gut venous effluent to bypass the liver
lead to PAVMs, which resolve when the shunt is closed (2). Further
evidence comes from single-ventricle patients who undergo a three-
staged surgery to relieve hemodynamic burden on the heart and
correct oxygen desaturation. The second-stage surgery, the
bidirectional Glenn, directs passively draining venous return from the
superior vena cava (SVC) to the pulmonary circulation, with venous
return from the inferior vena cava (IVC) pumped to the systemic
circulation. Although the Glenn effectively decreases ventricular
hemodynamic stress, intrapulmonary arteriovenous shunting is
pervasive, and up to 25% of Glenn patients develop clinically
significant hypoxemia secondary to diffuse PAVMs (3, 4). Although
early theories of PAVM development focused on the absence of
pulsatile flow or increased lower lobe perfusion (3), later evidence
implicated the exclusion of a liver-derived substance from the
pulmonary vasculature. This “hepatic factor” was postulated based on
correlation between laterality of PAVMs and laterality of exclusion of
hepatic venous effluent (5), and its existence is strongly supported by
evidence that the third-stage Fontan procedure (completion of the
total cavopulmonary anastomosis), which reroutes IVC flow to the
lungs without restoring pulsatility, is strongly associated with PAVM
regression (6). Despite the strong evidence for hepatic factor, its
identity remains unknown.
Approximately 80% of PAVMs are associated with hereditary
hemorrhagic telangiectasia, a genetic disorder caused primarily by
mutations in BMP (bone morphogenetic protein) receptors ENG
(endoglin) and ACVRL1 (activin A receptor like type 1, which
encodes ALK1) (7). This pathway is active in lung endothelium, and
ligands include BMP9 and BMP10 homodimers and BMP9/10
heterodimer (8, 9). Both BMP9 and BMP10 are transcribed in hepatic
stellate cells (9). Given the strong relationship between PAVMs and
hereditary hemorrhagic telangiectasia, the hepatic origins of BMP9 and
BMP10, and evidence of decreased plasma BMP9 in hepatopulmonary
syndrome (10), we hypothesized that ALK1 ligands may be the
hepatic factor required for PAVM prevention. We expect that hepatic
factor is either labile or actively removed from circulation on first pass
through the systemic circulation, making it unavailable to the lung
vasculature in Glenn circulation. Accordingly, in normal circulation,
we hypothesized that concentrations of ALK1 ligands would be
higher in the right atrium and pulmonary artery compared with the
SVC and infrahepatic IVC. Some of the results of these studies have
been previously reported in the form of an abstract (11), and some
have been previously reported in the form of a preprint (https://
doi.org/10.1101/2020.07.09.20148320).
Methods
This study was approved by the University of Pittsburgh Institutional
Review Board. Participants undergoing clinically indicated cardiac
catheterization were recruited between September 2015 and February
2017 and provided informed child assent and/or parental consent.
Patients with bidirectional Glenn, prior to Fontan, were compared with
two-ventricle control subjects. Excluded diagnoses among control
subjects included single ventricle physiology, unrepaired complex
congenital heart disease, and large shunt lesions. Patients with liver
disease, anemia (Hb ,8 g/dl), cardiac surgery within 30 days, or
transfusion within 48 hours were excluded from both cohorts.
We collected 1 ml blood in K2EDTA tubes from five sites: the
right atrium, pulmonary artery, aorta, SVC, and infrahepatic IVC.
We measured ligands in duplicate in 30 ml of plasma via sandwich
ELISAs (R&D Systems) using DY3209 (BMP9), MAB2926 and
BAF3956 (BMP10), and MAB2926 and BAF3209 (BMP9/10),
with in-house generated recombinant proteins for the latter two
standard curves. We fit data to a four-parameter logistic curve and
performed statistical analysis using GraphPad Prism. We ran all
samples from an individual on a single plate, and the operator was
blinded to sample identity. Sample volume limitations prevented us
from assaying all ligands in every individual.
Results
Diagnoses in 38 control subjects (mean age, 5.8 yr [4mo to 12.6 yr]; 21
males, 17 females) included small shunt lesions (21), repaired forms of
congenital heart disease with two-ventricle physiology (11), vascular
stenosis (5), valvar obstructive lesions (2), and hypertrophic
cardiomyopathy (1). Primary cardiac diagnoses in nine Glenn cases
(mean age, 2.9 yr [range, 22mo to 5.1 yr]; 7 males, 2 females) included
variants of hypoplastic left heart syndrome (5), pulmonary atresia
with intact ventricular septum (2), double outlet right ventricle with
pulmonary atresia (1), and heterotaxy with right atrial isomerism (1).
BMPs are generated as proprotein dimers that are cleaved
between the N-terminal prodomains and C-terminal growth factor
domains, releasing the disulfide-bonded GFD (growth factor dimer).
In control plasma, we detected BMP9 GFD, BMP10 proprotein, and
BMP9/10 GFD (Figure 1) but not BMP10 GFD (DY2926; R&D
Systems; data not shown). However, we found no differences in
plasma concentrations of any ALK1 ligand when comparing within-
subject values across the right atrium, pulmonary artery, aorta, SVC,
and IVC (Figure 1). This result suggests that these ligands are neither
particularly labile nor actively removed on first pass through the
systemic or pulmonary circulation, failing to support the hypothesis
that they represent the hepatic factor required to prevent PAVMs.
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